Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

GRHL1 acts as a tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3


ABSTRACT: Neuroblastoma is an embryonic solid tumor of neural crest origin and accounts for 11% of all cancer-related deaths in children. Novel therapeutic strategies are therefore urgently required. MYCN oncogene amplification, which occurs in 20% of neuroblastomas, is a hallmark of high risk. Here we aimed to exploit molecular mechanisms that can be pharmacologically addressed with epigenetically modifying drugs, such as histone deacetylase (HDAC) inhibitors. GRHL1, a gene critical for Drosophila neural development, belonged to the genes most strongly responding to HDAC inhibitor treatment of neuroblastoma cells in a genome- wide screen. An increase in the histone H4 pan-acetylation associated with its promoter preceded transcriptional activation. Physically adjacent, HDAC3 and MYCN co-localized t

ORGANISM(S): Homo sapiens

SUBMITTER: Johannes Fabian 

PROVIDER: E-GEOD-47407 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress